Literature DB >> 30237203

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Brigitte Michelsen1,2, Joseph Sexton3, Josef S Smolen4, Daniel Aletaha4, Niels Steen Krogh5, Désirée van der Heijde3,6, Tore K Kvien3, Merete Lund Hetland7,8.   

Abstract

OBJECTIVE: To test the psychometric performance of a modified Disease Activity index for PSoriatic Arthritis (DAPSA) using 28 instead of 66 swollen/68 tender joint counts (SJC/TJC).
METHODS: We included patients with psoriatic arthritis (PsA) from the Danish national quality registry DANBIO, divided into examination (n=3157 patients, 23987 visits) and validation cohorts (n=3154 patients, 24160 visits). We defined DAPSA28 = (28TJC × conversion factor1) + (28SJC × conversion factor2) + patient global (0-10VAS) + pain (0-10VAS) + C reactive protein (CRP) (mg/dL). Identification of the conversion factors was performed by generalised estimating equations in the examination cohort and evaluation of criterion, correlational and construct validity in the validation cohort.
RESULTS: We estimated DAPSA28 = (28TJC × 1.6) + (28SJC × 1.6) + patient global (0-10VAS) + pain (0-10VAS) + CRP (mg/dL). Criterion validity: DAPSA/DAPSA28 had comparable discriminative power expressed as standardised mean difference (DAPSA, 0.90; DAPSA28, 0.93) to distinguish between patients in high and low disease activity. Kappa with quadratic weighting of DAPSA/DAPSA28 disease activity states was high: 0.92 (95% CI 0.92 to 0.92). Standardised response means for DAPSA/DAPSA28 were -0.96/-0.92 for visits after biological DMARD-initiation. Correlational validity: Baseline DAPSA/DAPSA28 had high correlation with 28-joint disease activity score with CRP (r=0.87/r=0.93), simplified disease activity index (r=0.92/r=0.99), p<0.001. Bland-Altman plot showed better agreement between DAPSA/DAPSA28 for low than high disease activity. Construct validity: DAPSA/DAPSA28 were similarly correlated to Health Assessment Questionnaire; r=0.60/0.62, p<0.001. DAPSA/DAPSA28 discriminated patients reporting their symptom state as acceptable versus not acceptable equally well: mean (SD) 9.1 (8.7)/8.4 (8.0) and 24.2 (14.9)/22.5 (13.8), respectively.
CONCLUSION: Our study suggests that data sets with only 28-joint counts available can be used to calculate DAPSA28, especially in patients with low disease activity. DAPSA28 showed good criterion, correlational and construct validity and sensitivity to change. Still, our results support that 66/68 joint count should be performed and the original DAPSA should be preferred in PsA. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  disease activity; outcomes research; psoriatic arthritis

Mesh:

Year:  2018        PMID: 30237203     DOI: 10.1136/annrheumdis-2018-213463

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

Review 1.  Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.

Authors:  Sueli Carneiro; Penelope Esther Palominos; Sônia Maria Alvarenga Anti; Rodrigo Luppino Assad; Rafaela Silva Guimarães Gonçalves; Adriano Chiereghin; Andre Marun Lyrio; Antônio Carlos Ximenes; Carla Gonçalves Saad; Célio Roberto Gonçalves; Charles Lubianca Kohem; Cláudia Diniz Lopes Marques; Cláudia Goldenstein Schainberg; Eduardo de Souza Meirelles; Gustavo Gomes Resende; Lenise Brandao Pieruccetti; Mauro Waldemar Keiserman; Michel Alexandre Yazbek; Percival Degrava Sampaio-Barros; Ricardo da Cruz Lage; Rubens Bonfiglioli; Thauana Luíza Oliveira; Valderílio Feijó Azevedo; Washington Alves Bianchi; Wanderley Marques Bernardo; Ricardo Dos Santos Simões; Marcelo de Medeiros Pinheiro; Cristiano Barbosa Campanholo
Journal:  Adv Rheumatol       Date:  2021-11-24

2.  Fatigue and Associated Factors in an Immune-Mediated Inflammatory Disease Population: A Cross-Sectional Study.

Authors:  Francesco Salvatore Iaquinta; Rosa Daniela Grembiale; Daniele Mauro; Ilenia Pantano; Saverio Naty; Cristina Cosco; Daniela Iacono; Emanuela Gaggiano; Annarita Ruggiero; Francesco Ciccia; Patrizia Doldo; Rocco Spagnuolo
Journal:  J Clin Med       Date:  2022-04-27       Impact factor: 4.964

3.  Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.

Authors:  Omer Karadag; Ediz Dalkilic; Gizem Ayan; Orhan Kucuksahin; Timucin Kasifoglu; Neslihan Yilmaz; Suleyman Serdar Koca; Veli Yazisiz; Pinar Talu Erten; Mehmet Sayarlioglu; Mustafa Ender Terzioglu; Sukran Erten; Umut Kalyoncu
Journal:  Clin Rheumatol       Date:  2021-09-03       Impact factor: 2.980

4.  Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.

Authors:  Olafur Palsson; Thorvardur Jon Love; Anna Ingibjorg Gunnarsdottir; Petur Sigurdur Gunnarsson; Eydis Erla Runarsdottir; Niels Steen Krogh; Bjorn Gudbjornsson
Journal:  RMD Open       Date:  2019-07-16

5.  Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care.

Authors:  Brigitte Michelsen; Kristine Thomassen Berget; Jon Håvard Loge; Arthur Kavanaugh; Glenn Haugeberg
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.240

6.  Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.

Authors:  Johanna Elin Gehin; Guro Løvik Goll; David John Warren; Silje Watterdal Syversen; Joseph Sexton; Eldri Kveine Strand; Tore Kristian Kvien; Nils Bolstad; Elisabeth Lie
Journal:  Arthritis Res Ther       Date:  2019-11-29       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.